Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucerastat oral therapy in Japanese subjects with Fabry disease
jRCT2080224659Phase 3Completed
- Sponsor
- Idorsia
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lucerastat in Fabry disease (FD) (3 arms), sponsored by Idorsia. Primary endpoints: Change in plasma Gb3 concentration and Safety and tolerability of lucerastat. Started Apr 2019; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT2080224659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224659.